Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Regions; Segment Forecast, 2021 - 2028
- Published Date:May-2021
- Pages: 115
- Format: PDF
- Report ID: PM1869
- Base Year: 2020
- Historical Data: 2016 - 2019
Report Outlook
The global anticoagulant reversal drugs market was valued at USD 761.6 million in 2020 and is expected to grow at a CAGR of 14.4% during the forecast period. The key factors responsible for the market growth for anticoagulant reversal drugs include the rise in prevalence of bleeding disorders, innovation in drug therapies, and rising attention of key market players in the anticoagulant reversal drugs industry.
The anticoagulant reversal drugs market report details key market dynamics to help industry players align their business strategies with current and future trends. It examines technological advances and breakthroughs in the industry and their impact on the market presence. Furthermore, a detailed regional analysis of the industry at the local, national, and global levels has been provided.
Know more about this report: request for sample pages
The anticoagulant reversal drugs market has witnessed new approvals and launches by the players in the marketplace. For instance, in May 2020, U.S. based regulatory agency FDA has approved “Andexxa”, developed by Portola Pharmaceuticals. It is the first factor Xa inhibitor antidote. It is indicated when individuals suffering from un-controlled life-threatening bleeding in association with apixaban and rivaroxaban drugs.
Moreover, the company also announced the sale of “Ondexxya” in the Europe region, in August 2020, as there is a large pool of patients in Europe receiving Factor Xa inhibitor therapy. Andexxa has also received orphan drug designation and breakthrough therapy designation by FDA. It is also being researched that bleeding can also be triggered with the use of blood thinners such as warfarin, aspirin, and heparin.
According to the data published by the National Center for Biotechnology Information (NCBI), it is being found that bleeding cases increase with the use of warfarin and are estimated at around 15% - 20% cases per year. This is increasing at the rate of 1% - 3% annually. Hence, the demand for anticoagulants is further increasing the market demand for the reversal agents in anticoagulant therapy.
Know more about this report: request for sample pages
Anticoagulant Reversal Drugs Market Report Scope
The market is primarily segmented on the basis of product, distribution channel, and region.
|
By Product |
By Distribution Channel |
By Region |
|
|
|
Know more about this report: request for sample pages
Insight by Product
Idarucizumab market segment for anticoagulant reversal drugs accounted for the largest revenue share in 2020 and likely to witness the highest growth rate over the study period. This high share is attributed to its high potential and legacy drug being effective. Moreover, the drug is in more demand due to its high efficacy and specificity. However, the Andexanet alfa segment is projected to witness the highest growth rate over the assessment period. The expected growth is due to the approval of the anticoagulant reversal drug in key geographic markets.
For instance, in 2020, the Centers for Medicare & Medicaid Services (CMS) allocated a permanent reimbursement code J for the concerned drug Andexxa, facilitating an easy reimbursement system for the drug in the outpatient settings. Hence, a favorable reimbursement scenario for the drug in the major developed markets is projected to support the segment’s market growth prospects in anticoagulant reversal drugs industry.
Insight by Distribution Channel
The hospital pharmacy market segment accounted for the largest revenue share of anticoagulant reversal drugs industry in 2020. This high share is attributed to the fact that hospitals are considered primary health centers all over the globe. Hospitals are better equipped with emergency un-controlled bleeding disorders, both financially and skill-wise. Both government and private hospital chains have collaborations with insurance agencies to better take care of the indication.
However, retail pharmacy is expected to witness the highest market growth rate over the study period. This growth is primarily due to the rising importance of specialty drugs in the pharmacy business and is likely to have a positive impact on the segment’s market growth in anticoagulant reversal drugs industry. Moreover, the increasing establishment of retail pharmacies in emerging nations is also expected to boost the segment’s market growth in anticoagulant reversal drugs industry.
Geographic Overview
In 2020, the North America anticoagulant reversal drugs market accounted for over 35.0% share of the global market with the U.S. being the leading shareholder. Factors responsible for this include favorable reimbursement scenario in both U.S. and Canada, better-equipped specialty hospitals, and keen interest of market players in anticoagulant therapies.
Moreover, both countries have a skilled healthcare workforce and a huge pool of researchers involved in research & development activities, also complementing the region’s market growth for anticoagulant reversal drugs.
Competitive Insight
The prominent players operating in the market for anticoagulant reversal drugs are Portola Pharmaceuticals, CSL Behring, Bausch Health Companies Inc., Alps Pharmaceutical Ind. Co., Ltd, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Pfizer, Inc., Dr. Reddy's Laboratories, SG Pharma Pvt. Ltd., and Fresenius Kabi AG.
Want to check out the anticoagulant reversal drugs market report before buying it? Then, our sample report has got you covered. It includes key market data points, ranging from trend analyses to industry estimates and forecasts. See for yourself by downloading the sample report.
© 2024 Polaris Market Research and Consulting. All rights reserved
